BERKELEY HEIGHTS, N.J., May 3, 2011 (GLOBE NEWSWIRE) -- Genta Incorporated (OTCBB:GNTA) today announced that the Company has initiated a new clinical trial of tesetaxel in Korea as part of a comprehensive global initiative to replace standard taxanes as treatment for patients with advanced gastric cancer. In this trial, tesetaxel -- the leading oral taxane in clinical development -- will be combined with cisplatin and capecitabine (Xeloda®; Hoffmann LaRoche, Inc.) The new trial will open at the Severance Hospital, Yonsei University, in Seoul, Korea with Dr. Sun Young Rha, MD PhD, acting as lead investigator.
